Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Vyome completes merger with ReShape Lifesciences, to debut on Nasdaq as Vyome Holdings (HIND) on August 15
Vyome merges with ReShape Lifesciences, will trade on Nasdaq as Vyome Holdings (HIND) from August 15, focusing on immuno-inflammatory and rare diseases.
FDA delay shifts Neurizon Therapeutics (ASX: NUZ) ALS trial start — Can Q4 still deliver a win?
FDA delays decision on Neurizon’s NUZ-001 ALS trial to October, but manufacturing, regulatory, and trial readiness milestones keep Q4 start within reach.
UK approves first-ever immunotherapy for type 1 diabetes — can teplizumab really delay onset by three years?
MHRA approves teplizumab, the UK’s first immunotherapy for type 1 diabetes, delaying onset by three years. See how it could reshape care pathways.
Inside the new plan to end U.S. dependence on foreign drug ingredients — will it work this time?
Trump orders immediate filling of U.S. strategic API reserve with domestic production focus. See how this plan aims to secure critical medicine supply.
pH-D Feminine Health initiates landmark FDA-cleared Phase 3 trial for boric acid suppositories in yeast infection treatment
pH-D Feminine Health begins first FDA-cleared Phase 3 trial for boric acid suppositories, aiming for NDA approval and a breakthrough in recurrent yeast infection treatment.
Garden debuts BLOOM platform to accelerate IP compliance in AI drug discovery
Garden launches BLOOM, a real-time IP-aware AI drug design tool that speeds Markush searches by 32Ă—, reducing risks and accelerating discovery.
Equillium secures financing to launch EQ504 Phase 1 trial in 2026
Equillium secures up to $50M to fund clinical entry of EQ504 mid-2026—discover how this financing shapes its immunology strategy.
Why Sartorius Stedim Biotech’s NanoSpark deal could be the missing link in scalable NK cell therapies
Find out how Sartorius Stedim Biotech’s NanoSpark partnership and US$3M stake in Nanotein could reshape cell therapy manufacturing—read the full analysis.
Eli Lilly lifts 2025 outlook after Zepbound and Mounjaro drive 38% Q2 revenue surge
Eli Lilly’s Q2 2025 revenue jumped 38% to $15.56 billion, led by Zepbound and Mounjaro. Read how product growth is reshaping guidance.
Pfizer beats Q2 2025 earnings expectations and raises profit forecast, but long-term growth questions persist
Pfizer beats Q2 2025 estimates and raises profit guidance, but patent expirations and pricing pressures keep long-term growth questions on the table.